Sale

Cell Therapy Manufacturing Market

Global Cell Therapy Manufacturing Market Size, Share, Forecast: By Therapy Type: T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies, Others; By Technology; By Source of Cell; By Scale of Operation; By Applications; By End User; Regional Analysis; Market Dynamics: SWOT Analysis; Supplier Landscape; 2024-2032

Global Cell Therapy Manufacturing Market Outlook

The global cell therapy manufacturing market size was valued at USD 4.24 billion in 2023, driven by the increasing prevalence of chronic diseases and technological advancement in the cell therapies across the globe. The market size is anticipated to grow at a CAGR of 14.7% during the forecast period of 2024-2032 to achieve a value of USD 14.60 billion by 2032.

 

Cell Therapy: Introduction

The transplantation of human cells, which is performed to treat cells and tissues in the human body, is known as cell therapy. With the help of cell therapy, repairing and replacement of damaged cells and tissues is performed in the human body. In cell therapy, healthy cells are inserted into the body of a person whose body has unhealthy cells and tissues and are in need to be restored or replaced. A variety of diseases can be potentially treated using cell therapy, such as cancer, cardiovascular diseases, neurological disorders, autoimmune disorders, and genetic disorders.

 

Global Cell Therapy Manufacturing Market Analysis

The increasing advancements in stem-cell research is one of the key factors which are driving the growth of the market. With the help of these advancements, personalized cell therapies would soon become a reality, and some are already under process of development. Additionally, the presence of chimeric antigen receptor T-cell (CAR-T) cell therapy has gained significant popularity in the last few years. The increasing focus on the manufacturing and scalability of the processes is also anticipated to aid the cell therapy manufacturing market expansion. Closed system manufacturing and process optimization are now in focus due to the increasing commercialization of cell therapies.

 

Global Cell Therapy Manufacturing Market Segmentations

Market Breakup by Therapy Type

  • T-Cell Therapies
  • Dendritic Cell Therapies
  • Tumour Cell Therapies
  • Stem Cell Therapies
  • Others

 

Market Breakup by Technology

  • Somatic Cell Technology
  • Cell Immortalization Technology
  • Viral Vector Technology
  • Genome Editing Technology
  • Cell Plasticity Technology
  • 3D Technology
  • Others

 

Market Breakup by Source of Cell

  • Autologous Cell
  • Allogeneic Cell

 

Market Breakup by Scale of Operation

  • Preclinical
  • Clinical
  • Commercial

 

Market Breakup by Applications

  • Oncology
  • Cardiovascular Diseases
  • Orthopaedic Diseases
  • Others

 

Market Breakup by End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Others

 

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Global Cell Therapy Manufacturing Market Overview

The increasing prevalence of chronic diseases and technological advancement in cell therapies is primarily driving the cell therapy manufacturing market growth. After undergoing multiple observations and commercial practices, the efficiency and accuracy of mesenchymal stem cells, along with induced pluripotent stem cells, has provided positive responses from healthcare professionals about it. Their belief is that it can perform extensive tissue repair and immunomodulation with efficiency.

 

Due to the positive feedback, the demand for these cell therapies has increased and is expected to have a steady growth in the future. The educational institutions and research organization, along with key players present in the market, are collaborating with each other to provide and use resources and put them to better use by collaborating. The academical knowledge is used in research and development, which is further used to manufacture better therapies. With the immense potential of cell therapies, the global cell therapy manufacturing market demand has been witnessing steady growth and is expected to grow significantly in the coming years as well.

 

Global Cell Therapy Manufacturing Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Novartis AG
  • F.Hoffmann La Roche AG 
  • Gilead Sciences, Inc. 
  • Thermo Fischer Scientific, Inc. 
  • Catalent, Inc. 
  • JSR Life Sciences LLC (KBI Biopharma Inc) 
  • Waisman Center (Waisman Biomanufacturing) 
  • Cell and Gene Therapy Catapult 
  • Merck KGaA 
  • Lonza Group 
  • Oxford Biomedica Plc 
  • WuXi AppTec 
  • Charles River Laboratories International Inc. 
  • Institut Merieux (ABL Inc.) 
  • BioCentriq 
  • Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics) 
  • Amgen Inc. 
  • Bluebird Bio Inc. 
  • Takeda Pharmaceutical Company Limited

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

Therapy Type

  • Technology
  • Source of Cell
  • Scale of Operation
  • Applications
  • End User
  • Region
Breakup by Therapy Type
  • T-Cell Therapies
  • Dendritic Cell Therapies
  • Tumour Cell Therapies
  • Stem Cell Therapies
  • Others
Breakup by Technology
  • Somatic Cell Technology
  • Cell Immortalization Technology
  • Viral Vector Technology
  • Genome Editing Technology
  • Cell Plasticity Technology
  • 3D Technology
  • Others
Breakup by Source of Cell
  • Autologous Cell
  • Allogeneic Cell

Breakup by Scale of Operation

  • Preclinical
  • Clinical
  • Commercial
Breakup by Applications
  • Oncology
  • Cardiovascular Diseases
  • Orthopaedic Diseases
  • Others
Breakup by End User
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Novartis AG
  • F.Hoffmann La Roche AG 
  • Gilead Sciences, Inc. 
  • Thermo Fischer Scientific, Inc. 
  • Catalent, Inc. 
  • JSR Life Sciences LLC (KBI Biopharma Inc) 
  • Waisman Center (Waisman Biomanufacturing) 
  • Cell and Gene Therapy Catapult 
  • Merck KGaA 
  • Lonza Group 
  • Oxford Biomedica Plc 
  • WuXi AppTec 
  • Charles River Laboratories International Inc. 
  • Institut Merieux (ABL Inc.) 
  • BioCentriq 
  • Centre for Commercialization of Regenerative Medicine (CCRM) 
  • Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics) 
  • Amgen Inc. 
  • Bluebird Bio Inc. 
  • Takeda Pharmaceutical Company Limited

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Cell Therapy Manufacturing Market Overview
 
    3.1    Global Cell Therapy Manufacturing Market Historical Value (2017-2023) 
    3.2    Global Cell Therapy Manufacturing Market Forecast Value (2024-2032)
4    Global Cell Therapy Manufacturing Market Landscape
    4.1    Global Cell Therapy Manufacturing Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Cell Therapy Manufacturing Product Landscape
        4.2.1    Analysis by Type
        4.2.2    Analysis by Technology
        4.2.3    Analysis by Applications
5    Global Cell Therapy Manufacturing Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Cell Therapy Manufacturing Market Segmentation 
    6.1    Global Cell Therapy Manufacturing Market by Therapy Type
        6.1.1    Market Overview
        6.1.2    T-Cell Therapies
        6.1.3    Dendritic Cell Therapies
        6.1.4    Tumor Cell Therapies
        6.1.5    Stem Cell Therapies
        6.1.6    Others
    6.2    Global Cell Therapy Manufacturing Market by Technology
        6.2.1    Market Overview
        6.2.2    Somatic Cell Technology
        6.2.3    Cell Immortalization Technology
        6.2.4    Viral Vector Technology
        6.2.5    Genome Editing Technology
        6.2.6    Cell Plasticity Technology
        6.2.7    3D Technology
        6.2.8    Others
    6.3    Global Cell Therapy Manufacturing Market by Source of Cell
        6.3.1    Market Overview
        6.3.2    Autologous Cell 
        6.3.3    Allogeneic Cell
    6.4    Global Cell Therapy Manufacturing Market by Scale of Operation
        6.4.1    Market Overview
        6.4.2    Preclinical
        6.4.3    Clinical
        6.4.4    Commercial
    6.5    Global Cell Therapy Manufacturing Market by Applications
        6.5.1    Market Overview
        6.5.2    Oncology
        6.5.3    Cardiovascular Diseases
        6.5.4    Orthopedic Diseases
        6.5.5    Others
    6.6    Global Cell Therapy Manufacturing Market by End User
        6.6.1    Market Overview
        6.6.2    Pharmaceutical & Biotechnology Companies
        6.6.3    Academic & Research Institutes
        6.6.4    Others
    6.7    Global Cell Therapy Manufacturing Market by Region
        6.7.1    Market Overview
        6.7.2    North America 
        6.7.3    Europe
        6.7.4    Asia Pacific
        6.7.5    Latin America
        6.7.6    Middle East and Africa
7    North America Cell Therapy Manufacturing Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Cell Therapy Manufacturing Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Cell Therapy Manufacturing Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Cell Therapy Manufacturing Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Cell Therapy Manufacturing Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    Novartis AG
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    F.Hoffmann La Roche AG
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Gilead Sciences, Inc.
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Thermo Fischer Scientific, Inc.
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Catalent, Inc.
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    JSR Life Sciences LLC (KBI Biopharma Inc)
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Waisman Center (Waisman Biomanufacturing)
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Cell and Gene Therapy Catapult
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Merck KGaA
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Lonza Group
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    Oxford Biomedica Plc
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    WuXi AppTec
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
    17.13    Charles River Laboratories International Inc.
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications
    17.14    Institut Merieux (ABL Inc.)
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications
    17.15    BioCentriq
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications
    17.16    Centre for Commercialization of Regenerative Medicine (CCRM)
        17.16.1    Financial Analysis
        17.16.2    Product Portfolio
        17.16.3    Demographic Reach and Achievements
        17.16.4    Mergers and Acquisitions
        17.16.5    Certifications
    17.17    Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics)
        17.17.1    Financial Analysis
        17.17.2    Product Portfolio
        17.17.3    Demographic Reach and Achievements
        17.17.4    Mergers and Acquisitions
        17.17.5    Certifications
    17.18    Amgen Inc.
        17.18.1    Financial Analysis
        17.18.2    Product Portfolio
        17.18.3    Demographic Reach and Achievements
        17.18.4    Mergers and Acquisitions
        17.18.5    Certifications
    17.19    Bluebird Bio Inc.
        17.19.1    Financial Analysis
        17.19.2    Product Portfolio
        17.19.3    Demographic Reach and Achievements
        17.19.4    Mergers and Acquisitions
        17.19.5    Certifications
    17.20    Takeda Pharmaceutical Company Limited
        17.20.1    Financial Analysis
        17.20.2    Product Portfolio
        17.20.3    Demographic Reach and Achievements
        17.20.4    Mergers and Acquisitions
        17.20.5    Certifications
18    Global Cell Therapy Manufacturing Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 4.24 billion in 2023, driven by the increasing prevalence of chronic diseases and technological advancement in cell therapies.

The market is anticipated to grow at a CAGR of 14.7% during the forecast period of 2024-2032 and reach a market value of USD 14.60 billion by 2032.

The increasing prevalence of chronic diseases and technological advancement in cell therapies are significantly driving the market growth.

The increasing popularity of CART-T cell in the market is a major trend which is bolstering the growth of the market.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is major regional market.

The types of cell therapy in the market include T-cell therapies, dendritic cell therapies, tumour cell therapies, and stem cell therapies, among others.

The source of cells in the market can be divided into autologous cells and allogeneic cell.

The different scale of operations in the market are preclinical, clinical, and commercial.

Cell therapy finds wide applications in oncology, cardiovascular diseases, and orthopaedic diseases, among others.

The technologies used in cell therapy manufacturing are somatic cell technology, cell immortalization technology, viral vector technology, genome editing technology, cell plasticity technology, and 3d technology, among others.

The end users in the market include pharmaceutical and biotechnology companies, academic and research institutes, among others.

Key players involved in the market are Novartis AG, F.Hoffmann La Roche AG, Gilead Sciences, Inc., Thermo Fischer Scientific, Inc., Catalent, Inc., JSR Life Sciences LLC (KBI Biopharma Inc), Waisman Center (Waisman Biomanufacturing), Cell and Gene Therapy Catapult, Merck KGaA, Lonza Group, Oxford Biomedica Plc., WuXi AppTec, Charles River Laboratories International Inc., Institut Merieux (ABL Inc.), BioCentriq, Centre for Commercialization of Regenerative Medicine (CCRM), Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics), Amgen Inc., Bluebird Bio Inc., and Takeda Pharmaceutical Company Limited.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER